Your browser is no longer supported. Please, upgrade your browser.
Phathom Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-6.81 Insider Own17.16% Shs Outstand25.92M Perf Week4.18%
Market Cap1.50B Forward P/E- EPS next Y-3.76 Insider Trans-4.97% Shs Float9.71M Perf Month7.27%
Income-173.40M PEG- EPS next Q-1.01 Inst Own79.50% Short Float4.87% Perf Quarter2.55%
Sales- P/S- EPS this Y84.80% Inst Trans12.36% Short Ratio3.13 Perf Half Y30.37%
Book/sh6.03 P/B7.61 EPS next Y-10.30% ROA-69.00% Target Price54.50 Perf Year9.81%
Cash/sh6.94 P/C6.61 EPS next 5Y- ROE-88.70% 52W Range22.06 - 64.54 Perf YTD38.14%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-28.90% Beta-
Dividend %- Quick Ratio8.20 Sales past 5Y- Gross Margin- 52W Low108.02% ATR2.79
Employees25 Current Ratio8.20 Sales Q/Q- Oper. Margin- RSI (14)56.83 Volatility8.22% 5.63%
OptionableYes Debt/Eq0.30 EPS Q/Q52.60% Profit Margin- Rel Volume0.85 Prev Close44.17
ShortableYes LT Debt/Eq0.26 Earnings- Payout- Avg Volume150.79K Price45.89
Recom2.00 SMA202.27% SMA5013.94% SMA20017.12% Volume128,553 Change3.89%
Feb-17-21Initiated BMO Capital Markets Outperform $63
Feb-02-21Initiated Guggenheim Buy $60
Jun-26-20Downgrade Goldman Neutral → Sell $34
Nov-20-19Initiated Evercore ISI Outperform
Nov-19-19Initiated Needham Buy $40
Nov-19-19Initiated Jefferies Buy $32
Nov-19-19Initiated Goldman Neutral $32
Feb-17-21 10:12AM  
Feb-02-21 10:07AM  
Jan-19-21 08:30AM  
Dec-16-20 06:43PM  
Dec-15-20 04:01PM  
Dec-14-20 08:30AM  
Dec-08-20 09:00AM  
Dec-02-20 11:33PM  
Nov-30-20 04:05PM  
Nov-27-20 08:00AM  
Nov-19-20 04:05PM  
Nov-13-20 04:05PM  
Nov-10-20 04:05PM  
Nov-04-20 04:05PM  
Sep-09-20 08:30AM  
Aug-06-20 08:30AM  
Jul-13-20 08:30AM  
Jun-15-20 08:30AM  
Jun-12-20 10:25PM  
May-28-20 04:30PM  
May-12-20 08:30AM  
Apr-09-20 04:30PM  
Mar-19-20 08:30AM  
Feb-25-20 04:35PM  
Jan-16-20 09:00AM  
Jan-06-20 08:30AM  
Dec-23-19 08:30AM  
Dec-02-19 08:30AM  
Nov-26-19 08:30AM  
Nov-25-19 08:30AM  
Nov-13-19 04:05PM  
Oct-29-19 04:05PM  
Oct-25-19 05:10PM  
Oct-24-19 08:25PM  
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nabulsi AzmiChief Operating OfficerMar 02Sale45.909,127418,928794,700Mar 03 08:20 PM
Nabulsi AzmiChief Operating OfficerMar 01Sale45.855,373246,362803,827Mar 03 08:20 PM
Socks David ADirectorFeb 23Sale43.744,984217,9911,435,945Feb 23 06:14 PM
Socks David ADirectorFeb 22Sale45.6620,140919,5871,440,929Feb 23 06:14 PM
Socks David ADirectorFeb 19Sale47.1844,8762,117,0341,461,069Feb 23 06:14 PM
Nabulsi AzmiChief Operating OfficerFeb 02Sale40.979,084372,156809,200Feb 03 04:05 PM
Nabulsi AzmiChief Operating OfficerFeb 01Sale38.095,416206,285818,284Feb 03 04:05 PM
Socks David ADirectorJan 12Sale36.0727,165979,7951,532,945Jan 13 05:07 PM
Socks David ADirectorJan 11Sale34.9212,835448,2431,560,110Jan 13 05:07 PM
Socks David ADirectorDec 17Sale40.7448,2121,964,3761,572,945Dec 18 08:01 PM
Socks David ADirectorDec 16Sale47.5331,4461,494,5191,621,157Dec 18 08:01 PM
Nabulsi AzmiChief Operating OfficerDec 02Sale45.267,302330,512838,200Dec 03 06:01 PM
Nabulsi AzmiChief Operating OfficerDec 01Sale44.207,198318,176845,502Dec 03 06:01 PM
Socks David ADirectorNov 11Sale38.976,877268,0211,652,603Nov 12 04:13 PM
Socks David ADirectorNov 10Sale41.6912,681528,6721,659,480Nov 12 04:13 PM
Socks David ADirectorNov 09Sale42.3310,784456,5061,676,562Nov 12 04:13 PM
Nabulsi AzmiChief Operating OfficerNov 02Sale36.8314,500534,026852,700Nov 03 06:40 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerApr 01Buy24.86117,6002,923,6423,825,008Apr 03 04:30 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerMar 31Buy24.5530,600751,2643,707,408Mar 31 05:02 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerMar 27Buy24.6030,000738,0003,676,808Mar 31 05:02 PM